Activity-based proteome profiling of potential cellular targets of orlistat - An FDA-approved drug with anti-tumor activities

Journal of the American Chemical Society

Volumn 132, Issue 2, 2010, Pages 656-666

  Yang, Peng Yu ^a   Liu, Kai ^b   Ngai, Mun Hong ^a   Lear, Martin J ^a   Wenk, Markus R ^a   Yao, Shao Q ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY-BASED; ANTI-TUMOR ACTIVITIES; ANTICANCER DRUG; BIOLOGICAL PROPERTIES; BIOLOGICAL TARGETS; CANCER THERAPY; CELL-PERMEABLE; CELLULAR TARGETS; CLICK CHEMISTRY; FATTY ACID SYNTHASE; PROTEOME PROFILING; PROTEOMIC APPROACHES; RECOMBINANT PROTEIN EXPRESSION; SIDE EFFECT; SITE DIRECTED MUTAGENESIS; TARGET IDENTIFICATION; WESTERN BLOTTING;

ACETYLENE; DRUG INTERACTIONS; DRUG THERAPY; ENZYME ACTIVITY; FATTY ACIDS; PROBES; PROTEINS;

TARGETS;

CASPASE 8; FATTY ACID SYNTHASE; INITIATION FACTOR 2ALPHA; TETRAHYDROLIPSTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LACTONES; MOLECULAR CONFORMATION; MOLECULAR PROBES; PROTEOME; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74949101629     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja907716f     Document Type: Article

References (51)

1. (a) Giacomini, K. M.; Krauss, R. M.; Roden, D. M.; Eichelbaum, M.; Hayden, M. R.; Nakamura, Y. Nature 2007, 446, 975-977.
2. (b) Campillos, M.; Kuhn, M.; Gavin, A.-C.; Jensen, L. J.; Bork, P. Science 2008, 321, 263-266.
3. (c) Crunkhorn, S. Nat. Rev. Drug Discov. 2008, 7, 729-729.
4. Guerciolini, R. Int. J. Obes. Relat. Metab. Disord. 1997, 21 Suppl 3, S12-23.
5. (a) Kridel, S. J.; Axelrod, F.; Rozenkrantz, N.; Smith, J. W. Cancer Res. 2004, 64, 2070-2075.
6. (b) Pemble, C. W.; Johnson, L. C.; Kridel, S. J.; Lowther, W. T. Nat. Struct. Mol. Biol. 2007, 14, 704-709.
7. (c) Little, J. L.; Wheeler, F. B.; Fels, D. R.; Koumenis, C.; Kridel, S. J. Cancer Res. 2007, 67, 1262-1269.
8. (d) Knowles, L. M.; Axelrod, F.; Browne, C. D.; Smith, J. W. J. Biol. Chem. 2004, 279, 30540-30545.
9. (e) Knowel, L. M.; Yang, C.; Osterman, A.; Smith, J. W. J. Biol. Chem. 2008, 283, 31378-31384.
10. (f) Menendez, J. A.; Vellon, L.; Lupu, R. Ann. Oncol. 2005, 16, 1253-1267.
11. (g) Little, J. L.; Wheeler, F. B.; Koumenis, C.; Kridel, S. J. Mol. Cancer Ther. 2008, 7, 3816-3824.
12. (h) Kridel, S. J.; Lowther, W. T.; Pemble, C. W. Expert Opin. Investig. Drugs 2007, 16, 1817-1829.
13. (i) Menendez, J. A.; Vellon, L.; Lupu, R. Exp. Biol. Med. 2005, 230, 151-154.
14. (j) Carvalho, M. A.; Zecchin, K. G.; Seguin, F.; Bastos, D. C.; Agostini, M.; Rangel, A. L. C. A.; Veiga, S. S.; Raposo, H. F.; Oliveira, H. C. F.; Loda, M.; Coletta, R. D.; Graner, E. Int. J. Cancer 2008, 123, 2557-2565.
15. (k) Menendez, J. A.; Vellon, L.; Lupu, R. Int. J. Gynecol Cancer 2006, 16, 219-221.
16. (l) Browne, C. D.; Hindmarsh, E. J.; Smith, J. W. FASEB J. 2006, 20, 2027-2035.
17. (m) Cheng, F.; Wang, Q.; Chen, M.; Quiocho, F. A.; Ma, J. Proteins 2008, 70, 1228-1234.
18. Menendez, J. A.; Lupu, R. Nat. Rev. Cancer 2007, 7, 763-777.
19. (a) Ma, G.; Zancanella, M.; Oyola, Y.; Richardson, R. D.; Smith, J. W.; Romo, D. Org. Lett. 2006, 8, 4497-4500, and references cited therein.
20. (b) Richardson, R. D.; Ma, G.; Oyola, Y.; Zancanella, M.; Knowel, L. M.; Cieplak, P.; Romo, D.; Smith, J. W. J. Med. Chem. 2008, 51, 5285-5296, and references cited therein.
21. Filippatos, T. D.; Derdemezis, C. S.; Gazi, I. F.; Nakou, E. S.; Mikhailidis, D. P.; Elisaf, M. S. Drug Saf. 2008, 31, 53-65.
22. Uttamchandani, M.; Lu, C. H. S.; Yao, S. Q. Acc. Chem. Res. 2009, 42, 1183-1192.
23. (a) Evans, M. J.; Cravatt, B. F. Chem. Rev. 2006, 106, 3279-3301.
24. Uttamchandani, M.; Li, J.; Sun, H.; Yao, S. Q. ChemBioChem 2008, 9, 667-675.
25. Kalesh, K. A.; Yang, P.-Y.; Srinivasan, R.; Yao, S. Q. QSAR Comb. Sci. 2007, 26, 1135-1144.
26. Teo, Y.-C.; Tan, K.-T.; Loh, T.-P. Chem. Commun. 2005, 1318-1320.
27. Hoye, T. R.; Jeffrey, C. S.; Shao, F. Nat. Protoc. 2007, 2, 2451-2458.
28. Dieterich, D. C.; Link, A. J.; Graumann, J.; Tirrell, D. A.; Schuman, E. M. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 9482-9487.
29. Evans, M. J.; Saghatelian, A.; Sorensen, E. J.; Cravatt, B. F. Nat. Biotechnol. 2005, 23, 1303-1307.
30. Martin Moche, M.; Schneider, G.; Edwards, P.; Dehesh, K.; Lindqvist, Y. J. Biol. Chem. 1999, 274, 6031-6034.
31. Charron, G.; Zhang, M. M.; Yount, J. S.; Wilson, J.; Raghavan, A. S.; Shamir, E.; Hang, H. C. J. Am. Chem. Soc. 2009, 131, 4967-4975, and references cited therein.
32. (a) Mori, R.; Wang, Q.; Danenberg, K. D.; Pinski, J. K.; Danenberg, P. V. Prostate 2008, 68, 1555-1560.
33. (b) Phadke, M. S.; Krynetskaia, N. F.; Mishra, A. K.; Krynetskiy, E. J. Pharmacol. Exp. Therapeut. 2009, 331, 77-86, and references cited therein.
34. Kingston, D. G.; Newman, D. J. Curr. Opin. Drug Discov. Dev. 2007, 10, 130-144.
35. (a) Zhu, Y.; Lin, H.; Li, Z.; Wang, M.; Luo, J. Breast Cancer Res. Treat. 2001, 69, 29-38.
36. (b) Liu, Y.; Zhu, X.; Liao, S.; Tang, Q.; Liu, K.; Guan, X.; Zhang, J.; Feng, Z. Oncol. Rep. 2007, 18, 943-951.
37. (c) Wang, Y.; Cheong, D.; Chan, S.; Hooi, S. C. Int. J. Oncol. 2000, 16, 757-762.
38. (d) Vaarala, M. H.; Porvari, K. S.; Kyllonen, A. P.; Mustonen, M. V. J.; Lukkarinen, O.; Vihko, P. T. Int. J. Cancer 1998, 78, 27-32.
39. Commerically available antibody for RPL14 failed to detect even endogenous RPL14 and was thus not pursued further in our experiments.
40. (a) Böttcher, T.; Sieber, S. A. Angew. Chem., Int. Ed. 2008, 47, 4600-4603.
41. (b) Böttcher, T.; Sieber, S. A. J. Am. Chem. Soc. 2008, 130, 14400-14401.
42. (c) Böttcher, T.; Sieber, S. A. ChemBioChem 2009, 10, 663-666.
43. (a) Potashman, M. H.; Duggan, M. E. J. Med. Chem. 2009, 52, 1231-1246.
44. (b) Drahl, C.; Cravatt, B. F.; Sorensen, E. J. Angew. Chem., Int. Ed. 2005, 44, 5788-5809.
45. (c) Mukherji, D.; Spicer, J. Exp. Opin. Invest. Drugs 2009, 18, 293-301.
46. Boyle, G. A.; Govender, T.; Kruger, H. G.; Maguire, G. E. M. Tetrahedron: Asymmetry 2004, 15, 2661-2666.
47. Yin, J.; Yang, X. B.; Chen, Z. X.; Zhang, Y. H. Chin. Chem. Lett. 2005, 16, 1448-1450.
48. Schwabacher, A. W.; Lane, J. W.; Schiesher, M. W.; Leigh, K. M.; Johnson, C. W. J. Org. Chem. 1999, 63, 1727-1729.
49. Nguyen, T.; Francis, M. B. Org. Lett. 2003, 5, 3245-3248.
50. Liu, K.; Shi, H.; Xiao, H.; Chong, A. G. L.; Bi, X.; Chang, Y. T.; Tan, K.; Yada, R. Y.; Yao, S. Q. Angew. Chem., Int. Ed. 2009, 48, 8293-8297.
51. (b) Shi, H.; Liu, K.; Xu, A.; Yao, S. Q. Chem. Commun. 2009, 5030-5032.